¼¼°è ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå
Advanced Drug Delivery Systems
»óǰÄÚµå : 1536137
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 283 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

÷´Ü ¾à¹° Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3,624¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»ó

2023³â¿¡ 2,511¾ï ´Þ·¯·Î ÃßÁ¤µÈ ÷´Ü ¾à¹° Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ 2023-2030³â¿¡ CAGR 5.4%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 3,624¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °æ±¸ ¾à¹° Àü´ÞÀº CAGR 6.2%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 1,583¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Æó ¾à¹° Àü´Þ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 684¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ã·´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2023³â 684¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 765¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 8.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.1%¿Í 5.5%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

÷´Ü ¾à¹° Àü´Þ ½Ã½ºÅÛ(ADDS)Àº ÀǾà È­ÇÕ¹°ÀÇ Åõ¿© ¹× È¿´ÉÀ» Çâ»ó½ÃŰ´Â ±¤¹üÀ§ÇÑ ±â¼úÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¾à¹°À» Áúº´ ºÎÀ§¿¡ ƯÀÌÀûÀ¸·Î Ç¥ÀûÈ­Çϰí, ¾à¹° ¹æÃâ ¼Óµµ¸¦ Á¦¾îÇϰí, Ä¡·á ÀÛ¿ëÀÇ Áö¼Ó ½Ã°£À» ¿¬ÀåÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ADDSÀÇ ÁÖ¿ä À¯ÇüÀº ¸®Æ÷Á», ³ª³ëÀÔÀÚ, °æÇÇ ÆÐÄ¡, ÀÓº£µðµå µð¹ÙÀ̽º µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ³ª³ëÀÔÀÚ´Â Á¶Á÷ÀÇ ±íÀº ºÎºÐ±îÁö ħÅõÇÏ¿© ¼¼Æ÷ ¼öÁØÀ¸·Î Á÷Á¢ ¾à¹°À» Àü´ÞÇÒ ¼ö ÀÖÀ¸¸ç, °æÇÇ ÆÐÄ¡´Â ÇǺο¡¼­ Àå±â°£¿¡ °ÉÃÄ ¾à¹°À» ¹æÃâÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ç¥ÀûÈ­µÈ Á¢±Ù¹ýÀº ¾à¹°ÀÌ ÇÊ¿äÇÑ °÷¿¡ Á¤È®ÇÏ°Ô ÀÛ¿ëÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÇÊ¿äÇÑ ÃÑ·®À» ÁÙÀÓÀ¸·Î½á µ¶¼º ÀáÀç·ÂÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ °³¹ßÀº Àç·á°úÇÐ, »ý¸í°øÇÐ, ³ª³ë±â¼úÀÇ ÃֽйßÀü¿¡ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ½Åü¿Í ¾ÈÀüÇÏ°Ô »óÈ£ ÀÛ¿ëÇÏ°í Æ¯Á¤ »ý¹°ÇÐÀû Æ®¸®°Å¿¡ ¹ÝÀÀÇÏ¿© ¾à¹°À» ¹æÃâÇÒ ¼ö ÀÖ´Â »õ·Î¿î ¹°ÁúÀ» Áö¼ÓÀûÀ¸·Î ޱ¸Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì¸® °áÁ¤µÈ ¼Óµµ·Î ¿ëÇØµÇ´Â »ýºÐÇØ¼º ÁßÇÕü´Â ¾à¹° ¿ëÃâ ½ºÅÙÆ® ¹× ÀÓÇöõÆ®ÀÇ Á¦Á¶¿¡ »ç¿ëµË´Ï´Ù. ³ª³ë±â¼ú Ãø¸é¿¡¼­ µ§µå¸®¸Ó(°íµµ·Î ºÐÁöµÈ º° ¸ð¾çÀÇ °íºÐÀÚ)´Â ¾ÏÀ̳ª °¨¿°°ú °°Àº ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇϱâ À§ÇØ ¾à¹°°ú Ç¥Àû ºÐÀÚ¸¦ ºÎÂø½ÃŰ´Â À¯¸ÁÇÑ ÇÁ·¹ÀÓ¿öÅ©¸¦ Á¦°øÇÕ´Ï´Ù. Çϰí ÀÖ½À´Ï´Ù. ¾à¹° ¼öÁذú ȯÀÚÀÇ °Ç°­ ¸¶Ä¿¸¦ ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÏ´Â ¼¾¼­¸¦ Æ÷ÇÔÇÑ ADDS¿¡ ½º¸¶Æ® ±â¼úÀÇ ÅëÇÕµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ½Ç½Ã°£ µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ȯÀÚ ÇÑ »ç¶÷ÀÇ ¿ä±¸¿¡ ¸Â°Ô Ä¡·á¸¦ ÇÏ´Â º¸´Ù °³º°È­µÈ ÀÇ·á ½ÇõÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

÷´Ü ¾à¹° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼º ÁúȯÀÇ ºÎ´ã Áõ°¡, º¸´Ù È¿À²ÀûÀÌ°í Æí¸®ÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ¾à ¿¬±¸ °³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Æ÷ÇÔÇÑ ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ´ç´¢º´, ¾Ï, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯ÇàÀº Àå±â°£¿¡ °ÉÃÄ º¹ÀâÇÑ Ä¡·á ¿ä¹ýÀ» ÇÊ¿ä·ÎÇϱ⠶§¹®¿¡ Ä¡·á ÇÁ·ÎÅäÄÝÀ» ´Ü¼øÈ­ÇÏ°í ¾îµå·¹½ÌÀ» °³¼± ÇÒ ¼öÀִº¸´Ù È¿°úÀûÀÎ Àü´Þ ½Ã½ºÅÛÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ó°íÇÕ´Ï´Ù. °Ô´Ù°¡, °³ÀÎÈ­µÈ ÀÇ·áÀÇ ÃßÁøÀº °³º° ȯÀÚÀÇ ¿ä±¸¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â ¾à¹° Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. º¸´Ù Áøº¸ÀûÀÌ°í ³·Àº ħ½ÀÀûÀÎ Àü´Þ ¿É¼ÇÀÇ °³Ã´À» °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼úÀÇ ¹ßÀüµµ ÀÌ ½ÃÀåÀÇ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿¹¹æ °Ç°­ °ü¸®¿¡ ´ëÇÑ ¼ÒºñÀÚ ÇൿÀÇ º¯È­¿Í °¡Á¤¿ë ÀÚµ¿ ÁÖ»ç±â¿Í °°Àº Ä¡·áÀÇ ÀÚ°¡ Åõ¿©ÀÇ ¼ö¿ë È®´ë´Â ADDSÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀÌ °ãÄ¡´Â °ÍÀ¸·Î, ÷´Ü ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ¼¼°èÀÇ ÇコÄɾ Å« ¿µÇâÀ» ÁÙ °¡´É¼ºÀ» ºñ·ÔÇÑ, ´ÙÀ̳ª¹ÍÇÏ°í ±Þ¼ÓÇÏ°Ô ÁøÈ­ÇÏ´Â ºÐ¾ß°¡ µÇ´Â °ÍÀÔ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(Àü 86°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Advanced Drug Delivery Systems Market to Reach US$362.4 Billion by 2030

The global market for Advanced Drug Delivery Systems estimated at US$251.1 Billion in the year 2023, is expected to reach US$362.4 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Oral Drug Delivery, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$158.3 Billion by the end of the analysis period. Growth in the Pulmonary Drug Delivery segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$68.4 Billion While China is Forecast to Grow at 8.9% CAGR

The Advanced Drug Delivery Systems market in the U.S. is estimated at US$68.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$76.5 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Advanced Drug Delivery Systems Market - Key Trends and Drivers Summarized

Advanced drug delivery systems (ADDS) encompass a broad range of technologies that enhance the administration and efficacy of pharmaceutical compounds. These systems are designed to target drugs specifically to disease sites, control the rate of drug release, and increase the duration of therapeutic action, all while minimizing side effects. Key types of ADDS include liposomes, nanoparticles, transdermal patches, and implantable devices. Each system has its own unique mechanism of action: for instance, nanoparticles can penetrate deep into tissues to deliver drugs directly to the cellular level, while transdermal patches release medication through the skin over an extended period. This targeted approach not only improves patient outcomes by ensuring that the drug acts precisely where it is needed but also reduces the overall dosage required, thereby decreasing the potential for toxicity.

The development of these systems is heavily influenced by the latest advances in materials science, biotechnology, and nanotechnology. Researchers are continually exploring new materials that can safely interact with the body and respond to specific biological triggers to release drugs. For example, biodegradable polymers that dissolve at pre-determined rates are used to fabricate drug-eluting stents and implants. On the nanotechnology front, dendrimers — highly branched, star-shaped macromolecules — offer promising frameworks for attaching drugs and targeting molecules to address issues like cancer and infectious diseases effectively. The integration of smart technology into ADDS, such as sensors that monitor drug levels and patient health markers in real time, is also on the rise. These innovations are leading to more personalized medicine practices, where treatments can be tailored to the individual needs of each patient based on real-time data.

The growth in the advanced drug delivery systems market is driven by several factors, including the increasing burden of chronic diseases, the rising demand for more efficient and convenient therapeutic options, and significant investments in pharmaceutical R&D. The prevalence of chronic conditions like diabetes, cancer, and cardiovascular diseases, which require prolonged and often complex treatment regimens, has led to a need for more effective delivery systems that can simplify treatment protocols and improve adherence. Moreover, the push towards personalized medicine is increasing the demand for drug delivery systems that are adaptable to individual patient requirements. Technological advancements that enable the development of more sophisticated and minimally invasive delivery options also contribute to the expansion of this market. Additionally, the consumer behavior shift towards preventive healthcare and the growing acceptance of self-administration of treatments, such as auto-injectors for home use, are further catalyzing the growth of ADDS. The convergence of these factors ensures that advanced drug delivery systems continue to represent a dynamic and rapidly evolving field with significant potential for impacting global healthcare practices.

Select Competitors (Total 86 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â